CN1097306A - Compound anti-inflammation suppository - Google Patents
Compound anti-inflammation suppository Download PDFInfo
- Publication number
- CN1097306A CN1097306A CN 93112064 CN93112064A CN1097306A CN 1097306 A CN1097306 A CN 1097306A CN 93112064 CN93112064 CN 93112064 CN 93112064 A CN93112064 A CN 93112064A CN 1097306 A CN1097306 A CN 1097306A
- Authority
- CN
- China
- Prior art keywords
- infection
- suppository
- abdominal cavity
- inflammation
- compound anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of anti-inflammatory agent, particularly a kind of compound anti-inflammation suppository, it is to annotate film by the back that stirs in metronidazole powder, the semi-synthetic fatty acid glyceride of gentamycin sulfate powder in 55 ℃ of the ratio addings of filling a prescription to make suppository.Through appendectomy 1600 examples, its otch and abdominal cavity infection rate are 0%; Big gut surgery 800 routine infection of incisional wound rates are below 0.4%, and the abdominal cavity infection rate is 0%, are the ideal medicament of the infection of prevention operative incision, abdominal cavity infection and treatment anal orifice and rectal intestine inflammation disease.
Description
The present invention relates to a kind of anti-inflammatory agent, particularly a kind of compound anti-inflammation suppository is the ideal medicament of the infection of prevention operative incision, abdominal cavity infection and treatment anal orifice and rectal intestine inflammation disease.
Operation for appendicitis and big gut surgery belong to the bacterium operation, be defined as II, the operation of III class by textbook, its postoperative wound infection rate is than higher, along with antibiotic appearance and development, mostly after surgery is injection penicillin and streptomycin or quiet aminoglycoside antibiotics, though and the infection of incisional wound rate descends to some extent, report still at 5-30% according to domestic and foreign literature.Owing to the understanding to anaerobe, all using anaerobe resistant class medicine, carry out oral or quiet as metronidazole both at home and abroad over past ten years, still about 3-15%, the large intestine operative mortality is at 1-3% for its infection rate.Show that through domestic and international expert's clinical research result vermiform appendix, large intestine operative incision and its 80-100% of abdominal cavity infection are by due to anaerobe and the aerobe mixed infection, yet no matter described metronidazole still is an oral or quiet gentamycin, any medicine all can not be taken into account anaerobe and aerobe and infect, simultaneously find that also oral or quiet gentamycin abdominal cavity drug level is extremely low, so can not get a desired effect, patient in a single day operation infects, for a short time, then increase misery and financial burden, prolong the hospital stays, heavy then threat to life.
The object of the present invention is to provide that a kind of preparation technology is simple, medication is convenient, be not subjected to patient's fasting to influence, be beneficial to absorptions, effectively prevent infection of incisional wound, abdominal cavity infection, and to treating anal orifice and rectal intestine inflammation illness the compound anti-inflammation suppository of promising result is arranged.
Invention thought of the present invention is based on vermiform appendix, large intestine operative incision and abdominal cavity infection, its 80-100% is by the mechanism due to the mixed infection of anaerobe and aerobe, it is excellent that the medicine of anaerobe resistant and aerobe is gone out the optimum formula synergism by orthogonal Design Research, make it can prevent aerobe infection, anaerobic infection, can prevent the compound anti-inflammation suppository of mixed infection again, and then realize goal of the invention.
Compound anti-inflammation suppository of the present invention be composition, proportioning by prescription through being composited, its per thousand compositions, ratios are:
Metronidazole powder 500 grams
Gentamycin sulfate powder 66 grams
Semi-synthetic fatty glyceride adds to 4000 grams
Further specify summary of the invention by embodiment: semi-synthetic fatty glyceride 3434 grams that at first take by weighing Hongqi Pharmaceutical Factory's production dissolve for 80 ℃ ± 2 ℃ with heating in water bath, filter standby; Took by weighing metronidazole powder 500 grams of the Tianjin people pharmaceutical factory production of 80 mesh sieves, gentamycin sulfate powder 66 grams that Harbin Pharmaceutical Factory produces again respectively, to add till the limit edged is stirred to evenly in 55 ℃ the matrix solution with the dilution method that progressively increases behind both mix homogeneously, being incubated 55 ℃ of its pH values is 6.5; Above-mentioned admixing medical solutions is injected respectively in 1000 sterile-processed moulds, wait to be cooled to wipe off behind the room temperature and put into the refrigerator-freezer internal cooling and took out demoulding in 10 minutes, suppository is packed in the shell.
Gentamycin sulfate medicine in the prescription is few in gastrointestinal absorption by all putting down in writing this medicine in each textbook and the pharmacopeia, and the clinical confirmation abdominal cavity drug level of oral administration or quiet this medicine is extremely low, yet make behind the suppository from the anus medication with metronidazole is compound, find have a large amount of gentamycins to reach 60 μ g/ml in the abdominal cavity through the living animal and the intestinal capsule absorption test that exsomatizes.Thereby two kinds of recurrence due to taking drug in the explanation prescription synthesize suppository, and change application method, can be beneficial to absorption with being difficult for by the composition of gastrointestinal absorption, being converted into, and then realize goal of the invention, get a desired effect.
The present invention compared with prior art owing to two kinds of medicines of anaerobe resistant and aerobic bacteria, by matrix it is combined into suppository, has changed formulation and application method and has faced through appendectomy Bed 1600 examples, otch and abdominal cavity infection rate are 0%; Big gut surgery 800 examples, the otch infection rate is below 0.4%, and sense rate in abdominal cavity is 0%; And with domestic oral metronidazole commonly used and intramuscular injection gentamicin are by contrasting at random each 50 routine appendectomy patient at present, former method otch infection rate is 22%, and suppository is 0%; Again with the drip-feed gentamicin totally 162 its otch infection rates of example be 8.64% and suppository is 0%. Simultaneously medication is convenient, is not subjected to that patient's fasting affects, no pain, preparation technology are simple, be beneficial to and apply.
Claims (1)
- A kind of compound anti-inflammation suppository is characterized in that per thousand compositions, and proportioning is:Metronidazole powder 500 gramsGentamycin sulfate powder 66 gramsSemi-synthetic fatty glyceride adds to 4000 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93112064 CN1097306A (en) | 1993-07-12 | 1993-07-12 | Compound anti-inflammation suppository |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93112064 CN1097306A (en) | 1993-07-12 | 1993-07-12 | Compound anti-inflammation suppository |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1097306A true CN1097306A (en) | 1995-01-18 |
Family
ID=4989806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93112064 Pending CN1097306A (en) | 1993-07-12 | 1993-07-12 | Compound anti-inflammation suppository |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1097306A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023058A3 (en) * | 1998-10-16 | 2000-07-06 | Vitabiotics Limited | Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids |
| WO2006003043A1 (en) * | 2004-06-25 | 2006-01-12 | Cosmo Technologies Ltd. | Oral antimicrobial pharmceutical compositions |
-
1993
- 1993-07-12 CN CN 93112064 patent/CN1097306A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023058A3 (en) * | 1998-10-16 | 2000-07-06 | Vitabiotics Limited | Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids |
| WO2006003043A1 (en) * | 2004-06-25 | 2006-01-12 | Cosmo Technologies Ltd. | Oral antimicrobial pharmceutical compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4006224A (en) | Method and agent for treating inflammatory disorders of the gastrointestinal tract | |
| US3860708A (en) | Method of delivering the intestines of human beings from bariumsulphate after barium meal examination | |
| EP0349235A2 (en) | Niacin and guar-gum containing composition | |
| CN102028705A (en) | Gynecologic article containing biological antifungal components | |
| CN1097306A (en) | Compound anti-inflammation suppository | |
| CN101003539A (en) | Trometamol salt in compound of cillin category, and preparation method | |
| CN108324700A (en) | A kind of enteric slow release oxytetracycline calcium pre-mixing agent and preparation method thereof | |
| CN103059045B (en) | Amoxicillin sodium and clavulanate potassium compound and pharmaceutical composition thereof | |
| CN101297793A (en) | Injection for curing diarrhea of pig and preparation thereof | |
| CN1069647C (en) | Compound with broad-spectrum antibacterial action | |
| CN101209244B (en) | Method for producing acetylkitasamycin microcapsule type powder | |
| EP1790357B1 (en) | Perorally administrable antimicrobial composition | |
| Doman et al. | The hazard of drug-induced esophagitis | |
| CN100425229C (en) | Local medicine preparation containing antiinfective medicine composition and its preparing method | |
| CN105726491A (en) | Polyhexamethylene guanidine medicine for treating stomach disease and preparation method and application thereof | |
| CN101684083B (en) | Guanidyl alkanoylamino substituted tetracycline derivative | |
| CN1843505A (en) | Compound Doxycycline lysozyme enteral capsule | |
| US4500516A (en) | Antibacterial pharmaceutical composition | |
| CN1098076C (en) | Oral linmerjing as one kind of powerful anti-bacterial medicine | |
| Ehrenpreis et al. | Clostridium difficile-associated diarrhea after norfloxacin | |
| CN100418530C (en) | Ketoconazole eye drops and fabricating method thereof | |
| CN1020252C (en) | Prepn. of rifampin eye ointment | |
| CN103142587A (en) | Amoxicillin sodium-potassium clavulanate pharmaceutical composition and preparation method thereof | |
| CN108938746A (en) | A kind of amoxicillin powder and preparation method thereof | |
| RU1811848C (en) | Method for treating patients suffering from severe shigellosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |